8-K current report · filed Jul 7, 2026

Tvardi Therapeutics, Inc. (TVRD) 8-K Current Report: July 7, 2026

Item EX-99.1Item EX-99.2Item 7.01TVRD overview

Short answer

Tvardi Therapeutics, Inc. (TVRD) filed an 8-K current report with the SEC on July 7, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 7.01 (Regulation FD Disclosure). TTI-109 Phase 1 update: prodrug design confirmed with improved tolerability.

Tvardi Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • TTI-109 Phase 1 update: prodrug design confirmed with improved tolerability
  • Pharmacodynamic evidence of STAT3 target engagement, supporting the drug’s biological activity
  • Updated corporate presentation provides additional clinical context for investors and stakeholders

Item EX-99.1 · Exhibit EX-99.1

  • Phase 1 validated TTI-109’s prodrug conversion, dose-proportional exposure, and TTI-101-equivalent plasma levels
  • STAT3-driven Th17, Tfh, and B-cell populations fell by up to 60%, providing exploratory target-engagement evidence
  • Diarrhea duration improved substantially versus TTI-101: 0.46 days versus 3.35 days at near-equivalent doses
  • Planned Phase 2 dermatologic and GI programs remain contingent on IND clearance and additional funding
  • Positive data strengthen TTI-109’s development case, but healthy-volunteer results do not yet demonstrate clinical efficacy in patients

Item EX-99.2 · Exhibit EX-99.2

  • July 2026 investor presentation highlights TTI-109, an oral phosphate prodrug designed to improve TTI-101 delivery and gastrointestinal tolerability
  • Human Phase 1 data showed over 95% conversion to active TTI-101 at 2 hours and near-equivalent exposure versus TTI-101 400mg
  • Repeat dosing produced dose-proportional exposure above the 707ng/mL STAT3 IC50 across tested doses
  • TTI-109 reduced STAT3-driven Th17, T follicular helper and B-cell populations by up to 60% in healthy volunteers
  • Safety profile included no serious adverse events, with diarrhea incidence comparable to placebo and lower apparent duration than TTI-101

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Tvardi Therapeutics, Inc. 8-K filings

Get the next TVRD 8-K as it lands

Follow TVRD for push alerts, or ask the research agent what this filing means.